Pablo Rubinstein

During the 1980s, Pablo Rubinstein, M.D. pioneered the freezing of umbilical cord blood or placental blood cells to use for unrelated donors to treat diseases like Leukemia and genetic diseases such as Taysachs and Sickle Cell Anemia. He pioneered and established an international cord blood banking system and has played a leading role in international cord blood transplantation.

Medical Background
Earning his medical degree from the Universidad de Chile in 1962, Dr. Rubinstein completed a surgical residency at Hospital Clinico Jose Joaquin Aguiree in Chile and completed a fellowship at M.I. Bassett Hospital at Columbia University. He also finished an international fellowship at the National Institutes of Health at Mount Sinai Hospital in New York. He also taught as a professor at Universidad de Chile for four years.

History of Cord Blood Transplants
Following the first sibling-donor cord blood transplant in 1988, the National Institute of Health (NIH) awarded a grant to Dr. Rubinstein to develop the worlds first cord blood program at the New York Blood Center, in order to establish the inventory of stem cell units necessary to provide unrelated, matched grafts for patients.

In 1993, Dr. Joanne Kurtzberg, Duke University Medical Center, performed the first two successful unrelated donor cord blood transplants ; one of which cured acute lymphoblastic leukemia (ALL). As of 2006, more than 7,000 transplants from unrelated donors have been conducted on patients worldwide.

National Cord Blood Program
Dr. Rubinstein is co-founder and director, of the National Cord Blood Program at the New York Blood Center. Along with his wife and co-founder, Dr. Cladd Stevens, he and the program have enabled the inventory of umbilical cord blood units from ethnically diverse donors to grow, enabling it to serve the needs of patients across the world.

Medical Focus
Dr. Rubinstein specializes in immunogenetics, which encompasses the structure and function of genes that regulate immune responses, control the acceptance or rejection of tissue and organ transplants, and affect susceptibility to certain diseases.

He began in as an investigator at the Lindsley F. Kimball Research Institute at the NYBC, and serves as director of the Fred H. Allen Jr. Laboratory of Immunogenetics.

Dr. Rubinstein is also an adjunct clinical professor at Columbia University and is the author of more than 200 research papers on immunogenetics, cord blood banking and transplantation.

Stem Cell Advocate
Dr. Rubinstein has testified to the Senate and Congress on the importance of expanding funding Stem Cell research, and writes articles and papers on similar topics.

Related Information
This article incorporates public domain text from The U.S. National Library of Medicine and the National Institute of Neurological Disorders and Stroke.
 * National Center for Biotechnology Information's Research on Cord Blood
 * New Treatment for Bone Cancer
 * "A Medical Miracle Saved our Baby's Life", Redbook, 12/2002
 * CNN Report on Cord Blood
 * NY Times, "Umbilical Cord May Be Lifeline in Marrow Cases", November 26, 1998, by Denise Grady